Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002324 · ClinicalTrials.gov registry record · NA
Tailoring of Vaccine-Focused Messages: Disease Salience
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 1,320
- Enrollment target
NCT03002324 is a NA study that has completed, run by Emory University. The registered enrollment target is 1,320 participants.
The verdict
NCT03002324, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and Prevention (CDC) human papillomavirus (HPV) message, a new cervical cancer focused message developed by the study team, and a non-vaccine related control passage among parents of adolescent females. The goal of the trial will be to determine if the new cervical cancer framed message has an increased impact on intent to have daughters receive the HPV vaccine over the trial period as compared to the current CDC message used in the field. Additionally, the researchers will examine the impact both the CDC message and the new message individually have on intent to vaccinate when compared to the non-vaccine related control message. The participant's vaccine beliefs and intent to vaccinate will be assessed through an online survey at baseline. Two weeks later, participants will be randomized to view one of the three messages: the current CDC message, the cervical cancer framed message, or a non-vaccine related control message. Immediately afterwards, vaccine beliefs and intent to vaccinate will be assessed to determine the impact of the message.
Interventions
- BEHAVIORAL Baseline Survey
- BEHAVIORAL Control Message
- BEHAVIORAL Current CDC Message
- BEHAVIORAL Cervical Cancer Message
- BEHAVIORAL Post-Intervention Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002324
The ClinicalTrials.gov registry entry for NCT03002324 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Baseline Survey is the first listed.
NCT03002324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002324 about?
NCT03002324 is a clinical study titled "Tailoring of Vaccine-Focused Messages: Disease Salience". This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and Prevention (CDC) human papillomavirus (HPV) message, a new cervical cancer fo...
What is the current status of trial NCT03002324?
This trial is currently completed. It is a NA study. The enrollment target is 1,320 participants. The study started on 2017-01. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT03002324?
The interventions under investigation include: Baseline Survey (BEHAVIORAL), Control Message (BEHAVIORAL), Current CDC Message (BEHAVIORAL), Cervical Cancer Message (BEHAVIORAL), Post-Intervention Survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT03002324?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.